Your cart is empty
Browse our catalog to add research compounds.
Track known regulatory warnings, recalls, and safety alerts related to peptides from agencies worldwide.
Important Notice
This tracker is for informational purposes only. Always check official regulatory agency websites (FDA, Health Canada, TGA, MHRA, EMA, WADA) for the most current and authoritative information regarding recalls, warnings, and safety alerts.
Showing 15 of 15 alerts
FDA investigating reports of aspiration during anesthesia in patients on GLP-1 medications.
EMA's safety committee reviewed thyroid cancer signals with GLP-1 medications.
FDA updated the drug shortage status for Ozempic and Wegovy.
FDA raised concerns about compounded tirzepatide products.
FDA warned about bodybuilding supplements containing undeclared peptides and SARMs.
FDA alerted the public about counterfeit Ozempic (semaglutide) injection found in the U.S. drug supply chain.
TGA reminded consumers that research peptides are not approved for human use.
Health Canada warned about counterfeit Ozempic pens identified in the Canadian supply.
FDA warned consumers about risks of compounded semaglutide not approved by FDA.
FDA sent warning letters to companies marketing BPC-157 as a dietary supplement or drug.
FDA took enforcement action against clinics advertising peptide therapy.
Health Canada warned consumers not to use Melanotan products.
WADA updated the prohibited list to explicitly include additional peptides.
MHRA warned against use of injectable tanning products including Melanotan II.
TGA seized multiple shipments of Melanotan II entering Australia.